Anthera’s CFO and Chief Medical Officer explained the detailed plans for the blisibimod (B-mod) Phase III program at the recent Piper Jaffray conference.  The Phase III development program was blessed by the FDA in September and the EU regulatory agency in April. The first Phase III – CHABLIS1 will start where PEARL was done – Asia/Pacific/S.[…]

Anthera’s stock is down sharply since the last Issue. It appears that the company had been out trying to put together a private financing but could not execute the transaction.  Hurricane Sandy made it almost impossible to conduct business normally and ANTH was not able to close a transaction.  Alternatively, ANTH entered into an At Market[…]

Anthera’s stock is up since the last Issue as they have had two encouraging announcements. The most important was this week when they announced that an abstract from the Phase 2b PEARL-SC clinical study examining the treatment effect of blisibimod in systemic lupus patients has been accepted as a Late-Breaking poster presentation at the 2012 Annual[…]